Therefore, potential molecular mechanisms leading to the deregulation of FXR and PPARα activation possibly arising as a consequence of altered UGT1A activity in htgUGT1A-SNP mice are discussed and compared to the results of human population studies observed during NAFLD and NASH. Here, UGT1A1 is linked to metabolic dysfunction-associated steatotic liver disease.